$238.89
0.360.15%
Last update: Nov 12, 7:25 PM
ResMed Inc
RMDNYSE
ResMed fell 5.3% from $252.26 to $238.89, behind the S&P 500's +10.8%. Its worst day was Oct 30 (−9.1%), and its low came Jun 2 at $182.82.
Nov 12, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $2.81 beat the $2.71 estimate on $1.4B revenue (est. $1.4B).
+0.3% · S&P 500 −0.3%
ResMed closed at its highest level of the year, 9.4% above where the year started.
Story events cover the past 12 months · Times ET
+1.6% · S&P 500 +0.5%
EPS of $2.86 beat the $2.80 estimate on $1.4B revenue (est. $1.4B).
−4.1% · S&P 500 +0.3%
ResMed closed at its lowest level of the year, 27.5% below where the year started.
−1.9% · S&P 500 +0.1%
Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its MatrixCare business
−6.3% · S&P 500 −0.3%
EPS of $2.95 beat the $2.88 estimate on $1.5B revenue (est. $1.5B).
−5.1% · S&P 500 +0.6%
EPS of $2.91 beat the $2.67 estimate on $1.4B revenue (est. $1.4B); FY revenue guidance of $5.8B–$5.8B against the $5.8B consensus.
−9.1%, the year's worst day · S&P 500 −1.8%
Where it ended: a close of $238.89 on Nov 12, 2026. Up next: Q2 2027 earnings on Jan 28, 2027 (EPS est. $3.00, revenue est. $1.5B).
As of the Nov 12, 2026 close
Replay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RMD and SPY from Benzinga historical bars. Not investment advice.
